Raynaud's
phenomenon as the initial manifestation of
hypothyroidism
Coleman C.E.; Sessoms S.L.; Gowin K.M.; Boston
R.
Dr. S.L. Sessoms, 6550 Fannin Smith 1057,
Houston, TX 77030 United States
Journal of Clinical Rheumatology (United States)
1998, 4/5 (270-273)
A 38-year-old man, who presented with Raynaud
's phenomenon and no symptoms or signs of thyroid
hormone deficiency, was found to have
hypothyroidism . The Raynaud 's phenomenon
disappeared after 11/2 months of thyroid hormone
replacement therapy. We review four case reports
of Raynaud 's phenomenon that disappeared after
thyroid replacement therapy. We suggest that
thyroid deficiency should be considered a possible
cause of Raynaud 's phenomenon.
Drug
options for vasospastic disease
Coffman J.D.
Department of Medicine, Boston University School
of Medicine, Boston, MA United States
Drug Therapy (United States) 1992, 22/10
(45-48+53-56)
Estimates of the prevalence of Raynaud 's
phenomenon range from 5% to 30% of the US
population. Besides the primary disease, possible
causes of the condition include connective tissue
disease, carpal tunnel syndrome, arterial
obstructions, hypothyroidism , adverse drug
reactions, and use of vibrating tools. Although
simple measures, such as keeping the hands, feet,
and body warm, are effective in most patients,
drug therapy may be necessary when vasospastic
attacks interface with a patient's work or daily
activities. Calcium channel blockers,
sympatholytic agents, nitroglycerin,
triiodothyronine, captopril, and prostaglandins
have been used with varying degrees of success in
symptomatic patients. Nifedipine is the current
drug of choice.
Effect of
magnesium sulfate infusion on circulating levels
of noradrenaline and neuropeptide-Y-like
immunoreactivity in patients with primary
Raynaud's phenomenon
Leppert J.; Myrdal U.; Hedner T.; Edvinsson L.;
Tracz Z.; Ringqvist I.
Department of Research, University of Uppsala,
Central Hospital,S-721 89 Vasteras Sweden
Angiology (United States) 1994, 45/7
(637-645)
The effect of a short-term magnesium sulfate
(MgSOinf 4) infusion on venous plasma
concentration of noradrenaline (NA) and
neuropeptide-Y-like immunoreactivity (NPY-LI) was
investigated in 12 women with primary Raynaud 's
phenomenon (PRP) and in 12 healthy matched
controls. The Raynaud 's patients did not
demonstrate any significant changes in mean basal
plasma NA concentration (0.29 +/- 0.15 vs 0.37 +/-
0.09 ng/mL, ns) after MgSOinf 4 infusion. However,
in the controls there was more than twice the
amount of circulating noradrenaline (cNA) (0.21
+/- 0.14 vs 0.54 +/- 0.22 ng/mL, P < 0.001)
after MgSOinf 4 infusion, compared with the
preinfusion value. Measurements during the cold
pressor test prior to the MgSOinf 4 infusion
showed a significant increase of cNA in both the
PRP group and the control group (from 0.29 +/-
0.15 to 0.33 +/- 0.16 ng/mL, P < 0.05, and from
0.21 +/- 0.14 to 0.29 +/- 0.16 ng/mL, P <
0.005, respectively). After MgSOinf 4 infusion the
levels of cNA during the cold pressor test
increased significantly only in the PRP group
(from 0.37 +/- 0.09 to 0.41 +/- 0.11 ng/mL, P <
0.05). Circulating NPY-LI concentrations increased
significantly during MgSOinf 4 infusion in the
Raynaud 's patients as well as in the controls
from 105 +/- 21 to 127 +/- 23 pmol/L, P < 0.05,
and from 107 +/- 17 to 132 +/- 27 pmol/L, P <
0.01, respectively. There were no detectable
changes during the cold pressor tests in either
group. In healthy women short-term MgSOinf 4
infusion induced a sympathetic response, shown by
the increased concentration of cNA and NPY-LI,
while in PRP patients there was only an increase
in NPY-LI. The discrepancy between PRP patients
and healthy controls supports the view of a
so-called 'local fault' in the sympathetic nerve
terminal of arterial/arteriolar walls in Raynaud
's patients.
Thromboxane metabolite excretion in
patients with hand-arm vibration
syndrome.
Nowak J; Barregard L; Benthin G; Granung G;
Wennmalm A
Department of Clinical Physiology, Huddinge
University Hospital, Karolinska Institute,
Stockholm, Sweden
Clin Physiol (England) Jul 1996, 16 (4)
p361-7
As chronic exposure to hand-held vibrating
tools may cause endothelial injury, a subsequent
sustained platelet activation with the increased
release of vasoconstricting thromboxane A2 (TxA2)
could be of pathophysiological importance in
vibration-induced Raynaud 's phenomenon.
Therefore, the aim of this study was to elucidate
whether or not hand-arm vibration syndrome is
accompanied by increased endogenous TxA2
biosynthesis. The study involved 64 men, aged
23-61 years, stratified according to the exposure
to vibrating tools, the presence of Raynaud 's
phenomenon, and smoking habit. Forty of them were
car mechanics and 24 were age-matched healthy
volunteers who served as controls. The assessment
of platelet TxA2 formation in vivo was performed
by quantification of the urinary excretion of its
major metabolite, 2,3-dinorthromboxane B2
(2,3-dinor-TxB2), employing gas
chromatography-mass spectrometry. The average
urinary excretion rate of 2,3-dinor-TxB2 in
patients with Raynaud's phenomenon was 296 +/- 42
pg/mg creatinine and did not differ significantly
from the corresponding values in controls (328 +/-
62 pg/mg creatinine) or individuals exposed to
vibrating tools, but without any signs of
vasospastic disease (232 +/- 29 pg/mg creatinine).
The only statistically significant difference was
found between smokers and non-smokers (P <
0.001), a finding confirming the existence of
chronic platelet dysfunction in cigarette smokers.
The present data indicate that chronic exposure to
vibrating tools, with or without Raynaud 's
phenomenon, is not associated with an enhanced
platelet function as monitored by the urinary
excretion of 2,3-dinor-TxB2. Hence, a possible
vibration-induced vascular injury does not seem to
provide a stimulus sufficient to induce a
persistent platelet activation.
Raynaud's
phenomenon: State of the art 1998
Ho M.; Belch J.J.F.
J.J.F. Belch, University Department of Medicine,
Ninewells Hosp. and Medical School, Dundee DD1 9SY
United Kingdom
Scandinavian Journal of Rheumatology (Norway)
1998, 27/5 (319-322)
Raynaud 's Phenomenon (RP) is a relatively
common problem which may be troublesome and
difficult to treat in a minority of patients. The
state of the art in 1998 focusses on three key
areas: the clinical spectrum of RP; its
progression and prognosis; and its treatment. RP
is a systemic disease, with a multifactorial
aetiology and vasospasm affects not just the
digits and skin but also major organs including
the heart, lungs and kidneys. It is important to
distinguish primary from secondary RP. RP may
predate an associated connective tissue disease by
many years and markers for this include severe RP
symptoms with trophic skin changes, serological
abnormalities and abnormal nailfold capillaries.
Repeated attacks of vasospasm may cause ischaemic
reperfusion injury to the endothelium, resulting
in a vicious and self propagating cycle of cause
and effect. Nifedipine remains the 'gold standard'
of treatment but a number of new and promising
drugs, eg relaxin, are currently under
investigation. 'Vasodilator-plus' drugs, with the
ability to also modulate some of the
haemorrheological abnormalities in RP, are the
drugs that are going to have a major clinical
impact on the disease and hold promise for the
future.
Plasma
catecholamines during behavioral treatments for
Raynaud's disease.
Freedman RR; Keegan D; Migaly P; Galloway MP;
Mayes M
Lafayette Clinic, Detroit, MI 48207.
Psychosom Med (United States) Jul-Aug 1991, 53
(4) p433-9
We have previously demonstrated that the
vasospastic attacks of Raynaud's disease can be
induced despite blockade of efferent digital
nerves and that feedback-induced vasodilation is
mediated through a non-neural, beta-adrenergic
mechanism. Here, we sought to determine the role
of sympathetic activity, as measured by plasma
epinephrine and norepinephrine, during finger
temperature feedback and autogenic training .
Thirty-one female patients with idiopathic Raynaud
's disease were randomly assigned to receive
finger temperature feedback or autogenic training
over 28 days. Half of each group began and
finished training during the follicular phase of
the menstrual cycle, the other half during the
luteal phase. During training, significant
temperature elevations were shown by feedback
patients but not by autogenic patients. There were
no significant effects for norepinephrine and
epinephrine for either group. Cycle phase did not
interact with training effects or with
catecholamines. These findings do not support the
role of decreased sympathetic activation in
behavioral treatments for Raynaud s disease.
Quantitative measurements of finger
blood flow during behavioral treatments for
Raynaud's disease.
Freedman RR
Psychophysiology (United States) Jul 1989, 26 (4)
p437-41
Quantitative measurements of finger blood flow
have not been performed during temperature
biofeedback or other treatments for Raynaud 's
disease. In the present investigation, finger
blood flow was determined with venous occlusion
plethysmography, in addition to measurements of
finger temperature, heart rate, blood pressure,
and skin conductance level. After a maximum
vasodilation test, subjects received 10 sessions
of finger temperature biofeedback or autogenic
training . There were no group differences during
the maximum vasodilation test. During training,
temperature feedback subjects showed significant
elevations in finger blood flow, finger
temperature, and skin conductance level, whereas
those who received autogenic training did not.
These findings could not be explained by group
differences in other cardiovascular measures and
are consistent with previous studies suggesting
the involvement of an active vasodilating
mechanism in temperature feedback.
The
behavioral treatment of Raynaud's disease: a
review.
Rose GD; Carlson JG
Department of Psychology, University of Hawaii,
Honolulu 96822.
Biofeedback Self Regul (United States) Dec 1987,
12 (4) p257-72
Raynaud 's disease is a peripheral vascular
system disorder characterized by episodes of
vasoconstriction in the hands and feet resulting
in a lowering of skin temperature and pain. Recent
studies are reviewed that focus on the behavioral
treatment of Raynaud 's disease--in particular,
biofeedback and autogenic training .
Methodological problems and other difficulties
include the measurement of skin temperature,
schedules of reinforcement/feedback, and
characteristics of the experimenter and subject.
Studies in this area indicate some promise for
certain behavioral interventions, especially
finger temperature biofeedback under cold stress
conditions. On the other hand, further research is
needed to clarify the mechanisms, especially that
of vasodilation, and the applications of
temperature biofeedback , as well as the role of
attitudinal, interpersonal, and cognitive factors.
(43 Refs.)
Bringing
the feet in from the cold: thermal biofeedback
training of foot-warming in Raynaud's
syndrome.
Crockett D; Bilsker D
Biofeedback Self Regul (United States) Dec 1984,
9 (4) p431-8
The biofeedback -assisted treatment of a case
of Raynaud 's syndrome was examined in order to
determine the relationship between learning of the
hand-warming response and the subsequent ability
to produce foot-warming responses. It was found
that fluctuations in dermal hand and foot
temperatures were not significantly related,
either within or across treatment sessions. The
obtained hand-warming response was of high
magnitude and rapidly learned, while the
foot-warming response was more modest and took
substantially more trials to learn. These results
indicate that an easy generalization of the
hand-warming response cannot be assumed.
Behavioral treatment of Raynaud's
phenomenon in scleroderma.
Freedman RR; Ianni P; Wenig P
J Behav Med (United States) Dec 1984, 7 (4)
p343-53
Twenty-four patients with Raynaud 's phenomenon
and scleroderma were randomly assigned to receive
finger temperature biofeedback , frontalis EMG
biofeedback , or autogenic training . Only those
receiving temperature feedback showed significant
increases in finger temperature during training
and during a posttraining test of voluntary
control, effects not attributable to general
relaxation. However, no group demonstrated
significant clinical improvement, assessed by
symptom reports and by ambulatory monitoring of
finger temperature. The need for careful
classification of patients with Raynaud 's disease
and Raynaud 's phenomenon in scleroderma is
emphasized.
Biofeedback, autogenic training, and
progressive relaxation in the treatment of
Raynaud's disease: a comparative
study.
Keefe FJ; Surwit RS; Pilon RN
J Appl Behav Anal (United States) Spring 1980, 13
(1) p3-11
Twenty-one female patients suffering from
diagnosed idiopathic Raynaud's Disease were
trained to raise digital skin temperature using
either autogenic training , progressive muscle
relaxation, or a combination of autogenic training
and skin temperature feedback. Patients were
instructed in the treatment procedures in three
one-hour group sessions spaced one week apart. All
patients were instructed to practice what they had
learned twice a day at home. Patients kept records
of the frequency of vasospastic attacks occurring
over a four-week baseline period, and during the
first four weeks and the ninth week of training.
In addition, patients underwent four laboratory
cold stress tests during which they were
instructed to maintain digital temperature as the
ambient temperature was slowly dropped from 26
degrees to 17 degrees C. Cold stress tests were
given during week 1 of baseline and during weeks
1, 3, and 5 of training. No significant
differences between the three behavioral treatment
procedures were obtained. In addition, the ability
of patients to maintain digital temperature during
the cold stress challenge showed significant
improvement from the first to the last tests.
Symptomatic improvement was maintained by all
patients nine weeks after the start of training.
The implications of these findings for the
behavioral treatment of Raynaud 's Disease are
discussed.
Behavioral approaches to Raynaud's
disease.
Surwit RS
Psychother Psychosom (Switzerland) 1981, 36 (3-4)
p224-45
No abstract.
A
1-year follow-up of Raynaud's patients treated
with behavioral therapy techniques.
Keefe FJ; Surwit RS; Pilon RN
J Behav Med (United States) Dec 1979, 2 (4)
p385-91
The purpose of this study was to assess to what
degree learned control of digital temperature and
vasospastic attacks can be retained by Raynaud 's
patients over a full year period. Subjects were 19
patients suffering from diagnosed idiopathic
Raynaud 's disease who had undergone behavioral
training. These patients had been trained to
increase digital temperature using either
autogenic training , biofeedback , or a
combination of autogenic training and temperature
biofeedback . Results indicated that the mean
number of vasospastic attacks per day occurring 1
year after training was approximately equal to the
number occurring at the end of the initial
training (1.2-1.3 per day). Patient satisfaction
with the treatment program was above average (3.5
on a 5-point scale). The patients' ability to
maintain digital temperature during the cold
stress challenge was imparied, however. At 1-year
follow-up, digital temperature readings taken in
the laboratory were identical to baseline
levels.
Behavioral treatment of Raynaud's
disease.
Surwit RS; Pilon RN; Fenton CH
J Behav Med (United States) Sep 1978, 1 (3)
p323-35
In order to assess the efficacy of a behavioral
intervention in the treatment of idiopathic
Raynaud's disease, 30 female patients were trained
to control their digital skin temperature using
autogenic training or a combination of autogenic
training and skin temperature feedback either in
the laboratory or at home. All trained subjects
demonstrated a significant ability to maintain
digital skin temperature in the presence of a cold
stress challenge and reported significant
reductions in both frequency and intensity of
vasospastic attacks. The addition of skin
temperature feedback to autogenic training did not
provide additional clinical benefit.
Long-term effectiveness of behavioral
treatments for Raynaud's disease
Freedman R.R.
Lafayette Clinic, Wayne State University,
Detroit, MI 48207 United States
Behavior Therapy (United States) 1987, 18/4
(387-399)
Raynaud 's disease is characterized by episodic
digital vasospasms of unknown etiology. Although
surgical and pharmacologic treatments have been
problematic, behavioral procedures have shown
considerable efficacy. Temperature biofeedback
reduces reported symptom frequency and enables
patients to voluntarily incrfease finger
temperature and capillary blood flow for 1 year
after treatment. Symptomatic improvement persists
for up to 3 years. This procedure is mediated by a
nonneural beta-adrenergic vasodilating mechanism
rather than through physiological relaxation.
Relaxation-based procedures, such as autogenic
training , produce smaller symptom reductions at
one-year follow-up with no retention of
physiological effects. The effects of classically
conditioned vasodilation are retained for 1 year
in normal persons and may be of value in the
treatment of Raynaud 's disease.
Biofeedback training in clinical
cardiovascular disease
Surwit R.S.
Dept. Med. Psychol., Duke Univ. Med. Cent.,
Durham, N.C. United States
Primary Cardiology (United States) 1980, 6/9
(34-48)
Biofeedback mechanisms have been shown to be
effective in treating mild hypertension. Various
forms include binary feedback training to lower
blood pressure and heart rate, analogue feedback
to control forearm and frontalis electromyographic
activity, and meditation-relaxation procedures.
The simple technique of having the patient take
his own blood pressure and consciously attempt to
lower it by whatever mechanism he can is quite
effective. Thermal feedback training to control
migraine headaches and Raynaud 's disease has been
successful. Autogenic training to control skin
temperature is also an effective instrument.
[Esophageal motor abnormalities,
gastroesophageal reflux and duodenogastric reflux
in patients with Raynaud's disease]
Pucciani F; Bechi P; Pantalone D; Panconesi R;
Paparozzi C; Pagliai P; Cortesini C
Clin Ter (Italy) Dec 31 1989, 131 (6) p373-80
Twenty-four patients with Raynaud 's
phenomenon, without ARA criteria for
classification, were examined, after clinical
history, by means of esophageal manometry,
combined gastric and esophageal pH-monitoring,
endoscopy. The results showed in these patients a
high incidence of esophageal motor abnormalities
(66.6%), of gastroesophageal reflux (50%), and of
duodenogastric reflux (45.8%).
[Clinical studies on various therapy
for the intractable trauma of toes and fingers in
cases of diabetes mellitus and peripheral ischemic
diseases]
Kuyama T; Umemura H; Sudo T; Kawamura M; Shobu
R; Tsubakimoto R; Nishimoro A
Second Department of Surgery, School of Medicine,
Kinki University, Osaka, Japan.
Nippon Geka Gakkai Zasshi (Japan) May 1988, 89
(5) p763-70
In cases of ischemic extremities and diabetes
mellitus, the trauma on finger and toe is very
intractable. For such injuries amputation of
extremity is indicated very often because of
severe necrosis. The number of such cases has been
increasing recently because many cases of these
patients have arteriosclerotic arterial occlusion
and diabetes mellitus, and these are correlated
with the changes of aging. The number of cases of
Buerger's disease has been also increasing and it
is another etiology of intractable trauma in
ischemic extremity. The repeated hyperbaric
oxygenation, sympathetic block, warfarin therapy
and insulin bath with bubbling of hyperbaric
oxygen , were applied to has been of such
necrosis. By these procedures, the rate of
amputation of extremity decreasing. It was
concluded that the surgical reconstruction of
artery for ischemic extremity has never any
meaning as the therapy of such intractable
injuries, if blood flow in the peripheral tissue
is not kept physiologically, before vascular
reconstruction. In order to increase peripheral
tissue circulation, the hyperbaric oxygenation,
sympathetic block and warfarin therapy wer
performed in many cases and these methods were
very effective for intractable injuries with
severe necrosis.
'Phenomenon of hyperbaric
accumulation of venous partial pressure of oxygen'
concerning the hyperbaric therapy and lumbosacral
sympathetic ganglionectomy Linf 2 and Linf 3 for
healing of incurable wounding in patients with
periphery circulatory disturbances
Kuyama T.; Tanabe H.; Umemura H.; Yabumoto
E.
II Dept. Surg., Kinki Univ. Sch. Med., Osaka
Japan
Acta Medica Kinki University (Japan) 1976, Vol.
1/- (1-16)
The authors reported the results of the
hyperbaric therapy for patients with the disease
which may have a genetic origin in part, namely
certain forms of cancer and L.E.Raynaud 's
syndrome, and furthermore, thromboangiitis
obliterans which have a unclear origin and in
addition Raynaud 's syndrome, chronic stage of
arteritis luetica and ulcus cruris. The clinical
results, finding, interpretations and implications
are discussed. The phenomena of hyperbaric
accumulation of venous partial pressure of oxygen
are described and the authors supposed that wound
healing of ischemic ulcers caused by successive
hyperbaric oxygenation were due to subepithelial
and in granulations of ulcers revascularity of
capillaries. The above facts were assumed on the
basis of the clinical results of thermocamera,
optical pulse wave calculation and plasma
ultra-centrifugation lipoprotein fraction,
relating with decrease in sympathetic
irritation.
Micronutrient antioxidant status in
patients with primary Raynaud's phenomenon and
systemic sclerosis.
Herrick AL; Rieley F; Schofield D; Hollis S;
Braganza JM; Jayson MI
University of Manchester Rheumatic Diseases
Centre, Hope Hospital, Salford, UK.
J Rheumatol (Canada) Aug 1994, 21 (8)
p1477-83
OBJECTIVE. To investigate the possibility that
micronutrient antioxidant status is an important
factor in determining the severity of Raynaud 's
phenomenon (RP) and in differentiating between
patients with primary Raynaud 's phenomenon (PRP)
and those in whom Raynaud 's is secondary to
systemic sclerosis (SSc).
METHODS. Four micronutrient antioxidants
(selenium, vitamin E , beta-carotene and ascorbic
acid) and 2 "markers" of free radical associated
activity were assayed in peripheral blood from 10
patients with PRP, 9 with limited cutaneous SSc
(ISSc), 9 with diffuse SSc (dSSc) and 15 healthy
control subjects.
RESULTS. Plasma ascorbic acid was reduced in
all 3 groups of patients: median level 10.6 mg/l
in controls, 4.8 mg/l in PRP (p < 0.01), 2.5
mg/l in ISSc (p < 0.01) and 6.8 mg/l in dSSc (p
< 0.05). A reduction in serum selenium was
especially found in dSSc (median 75 micrograms/l
compared to 100 micrograms/l in controls, p <
0.05). In keeping with these deficiencies, the
serum concentration of 9, 11, linoleic acid was
elevated in RP patients: median values for the
molar ratio of the isomer to the parent fatty acid
were 1.91% in controls, 3.70% in ISSc (p <
0.05) and 3.85% in dSSc (p < 0.01). Smoking
patients showed lower levels of ascorbic acid and
higher levels of the linoleic isomer than
nonsmokers.
CONCLUSION. Deficiencies of ascorbic acid and
selenium may predispose towards irreversible
tissue injury in RP patients and cigarette smoke
may be an independent risk factor. Micronutrient
antioxidant supplements may be of therapeutic
value.
[Thermographic assessment of
Raynaud's phenomenon in childhood mixed connective
tissue disease]
Yokota S; Kuriyama T; Takahashi Y; Mori M;
Shike H; Ibe M; Mitsuda T; Aihara Y
Department of Pediatrics, Yokohama City
University School of Medicine.
Ryumachi (Japan) Dec 1994, 34 (6) p955-60
To assess Raynaud 's phenomenon objectively,
thermographic estimation of hands and fingers was
performed before and after the disease- and
Raynaud 's phenomenon-directed therapy in 3
children with mixed connective tissue disease. All
the cases were positive in Raynaud 's phenomenon,
and the surface temperature of their hands and
fingers were decreased even before cold challenge.
After the cold provocation test at 4 degrees C for
10 sec., the temperature of all or some of the
fingers were rapidly decreased, and the recovery
of surface temperature of these fingers were
markedly delayed. Even after methylprednisolone
pulse therapy the pattern of the finger
temperature were essentially unchanged, suggesting
that steroids are not effective in the treatment
of Raynaud's phenomenon. The long-term
administration of vitamin - E , oral prostaglandin
E1, and/or serotonin-receptor inhibitor were also
proved to be not beneficial in improving Raynaud
's phenomenon. Thus, thermography is useful in
diagnosing Raynaud 's phenomenon objectively, in
determining the efficacy of anti-Raynaud drugs,
and in estimating long-term course of the
phenomenon.
Is
vitamin E involved in the autoimmune
mechanism?
Ayres S Jr; Mihan R
Cutis (United States) Mar 1978, 21 (3) p321-5
Autoimmune diseases are characterized by an
alteration of the body's defense mechanism,
designed for protection against infections and
toxic injuries, which for unknown reasons attacks
and destroys normal tissue. Some evidence strongly
suggests that such diseases are the result of
hydrolytic enzymes that escape from lysosomes
whose membranes have been damaged by lipid
peroxidation or other causes and that combine with
and denature normal tissue proteins--in effect
converting them into foreign proteins--to which
the body then reacts by producing antibodies.
During the past ten years, in a private
dermatologic practice, we have conducted clinical
investigations on the possible therapeutic value
of vitamin E in the management of a number of
disabling skin diseases of unknown etiology as
well as several muscular disorders. Among the
diseases that were successfully controlled were a
number in the autoimmune category, including
scleroderma, discoid lupus erythematosus,
porphyria cutanea tarda, several types of
vasculitis, and polymyositis. Since vitamin E is a
physiologic stabilizer of cellular and lysosomal
membranes, and since some autoimmune diseases
respond to vitamin E , we suggest that a relative
deficiency of vitamin E damages lysosomal
membranes, thus initiating the autoimmune
process.
Comparative double-blind trial of
dl-alpha-tocopheryl nicotinate on vibration
disease.
Matoba T; Kusumoto H; Mizuki Y; Yamada K
Tohoku J Exp Med (Japan) Sep 1977, 123 (1)
p67-75
Sixty inpatients with vibration disease were
examined on the effect of dl-alpha-tocopheryl
nicotinate by comparative double-blind study. The
observed period was 6 weeks and the dose was 6
capsules a day (600 mg as dl-alpha-tocopheryl
nicotinate, Juvela Nicotinate, referred to as EN).
The physical exercise therapy was applied to all
patients throughout the test period. EN group
became better with a significant difference from P
(placebo) group in the subjective symptoms, the
clinical examinations and the collective improving
rate (p less than 0.01, 0.05, 0.01), respectively.
The improvement of the subjective symptoms of both
groups was higher 6 weeks than 3 weeks after
administration. Most items in EN group became
better significantly (p less than 0.05) as
compared with those in P group. The examinations
of the peripheral functions in EN group showed a
significant improvement 6 weeks after
administration in comparison with those in P
group. Blood chemistry, blood cell counts and
serum electrolytes changed within normal range.
Thus, this preparation would be a curative agent
for patients with vibration disease.
[The
effect of dimethyl sulfoxide on the
thromboelastographic indices and the
microcirculation in patients with rheumatic
diseases]
Murav'ev IuV; Loskutova TT; Anikina NV;
Shcherbakov AB; Sokolov VB
Ter Arkh (USSR) 1989, 61 (12) p106-9
Using a blind method for assessing the results,
a study was made of the effect of
dimethylsulfoxide (DMSO) on fibrin formation and
microcirculation in 42 patients with rheumatic
diseases (rheumatoid arthritis, systemic
scleroderma, Raynaud 's syndrome). It has been
shown that the therapeutic effect of DMSO in
rheumatic diseases is determined to a definite
degree by its normalizing action on fibrin
formation and microcirculation.
Pathophysiology of capillary
circulation: Raynaud's disease.
Arnot RS; Boroda C; Peacock JH
Angiology (United States) Jan 1978, 29 (1)
p48-52
Despite the frequency of Raynaud 's disease in
cold climates, the etiology of the condition
remains uncertain. This report reviews the
literature since Raynaud 's original description
and Lewis and Pickering's addition to the concept,
and several recent observations which add to our
understanding of the disease are discussed. We
investigated the effect of posture and a
vasodilator drug on the digital capillary
circulation; digital blood flow increases as the
body moves from a recumbent, through a sitting, ti
an upright position. Bradilan, a vasodilator drug,
increases the circulation in the recumbent and
sitting positions, but has no effect in standing
patients, despite symptomatic relief.
Vasodilator drugs in peripheral
vascular disease
Coffman J.D.
Boston Univ. Sch. Med., Boston, Mass. United
States
New England Journal of Medicine (United States)
1979, 300/13 (713-717)
In vasospastic diseases, vasodilator drugs that
act upon the sympathetic nervous system may have a
beneficial effect in many patients by increasing
cutaneous capillary blood flow. These agents may
decrease persistent vasospasm or the number and
intensity of attacks in Raynaud 's phenomenon but
usually do not produce complete relief. Full
benefit is often prevented by unpleasant and
sometimes severe side effects that limit dosage.
Reserpine or guanethidine is the drug of choice;
tolazoline long-acting tablets are added when
further relief is needed. Papaverine, niacin ,
isoxsuprine and cyclandelate are representative of
vasodilator drugs that directly relax vascular
smooth muscle. When administered by mouth, these
drugs are not potent peripheral vasodilators, and
it may be concluded that they are not of value in
the treatment of peripheral vascular diseases.
Review of the clinical studies of vasodilator
drugs in obstructive vascular disease reveals
little substantive evidence to support their use.
They are not effective in the treatment of either
intermittent claudication or ischemic symptoms or
signs at rest. They fail to increase blood flow in
most patients with ischemic limbs, even when
administered locally by the intra-arterial route.
No drug has been shown to increase muscle blood
flow during exercise when patients with
intermittent claudication experience symptoms.
Treatment of the Raynaud's phenomenon
with piracetam.
Moriau M; Lavenne-Pardonge E; Crasborn L; von
Frenckell R; Col-Debeys C
Department of Internal Medicine, University of
Louvain, UCL, Brussels Belgium.
Arzneimittelforschung (Germany) May 1993, 43 (5)
p526-35
Piracetam (Nootropil, CAS 7491-74-9) has been
investigated in the treatment of primary and
secondary Raynaud 's phenomenon in three
sequential and complementary studies. The first
study in 20 patients with primary Raynaud 's
phenomenon, utilising clinical and ultrasound
examination, capillaroscopy and laboratory tests
established a daily dose of 8 g as most effective.
The second study in 58 patients (47 primary, 11
secondary) confirmed the therapeutic efficacy of
piracetam in both primary and secondary Raynaud 's
phenomenon. The third study, of crossover design,
in 30 patients with severe Raynaud 's syndrome,
examined various agents given singly or in
combination. The results not only confirmed the
efficacy of piracetam but in addition allowed
comparison of the efficacy of the principal
therapeutic agents or regimens used in the
treatment of Raynaud 's syndrome and the
formulation of a list of these therapies in
decreasing order of efficacy, thus: piracetam 4
g/d + buflomedil 600 mg/d; piracetam 8 g/d;
buflomedil 600 mg/d; piracetam 4 g/d +
acetylsalicylic acid 100 mg/d; pentoxifylline 1200
mg/d; calcium antagonists; ketanserin 120 mg/d.
The particular efficacy of 8 g piracetam daily in
3 divided doses at 8-hourly intervals can be
attributed to its unique dual mode of action;
inhibition of platelet function by inhibition of
thromboxane A2 synthetase or antagonism of
thromboxane A2 and increased formation of
prostaglandin I2, together with a rheological
effect involving reduction in blood and plasma
viscosity through an increase in cell membrane
deformability and a reduction of 30-40% in the
plasma concentrations of fibrinogen and von
Willebrand's factor. In addition, the
administration of piracetam appears to be devoided
of adverse effects.
Comprehensive management of Raynaud's
syndrome
Merritt W.H.
Dr. W.H. Merritt, Plastic and Reconstructive
Surgery, 2002 Bremo Road, Richmond, VA 23226
United States
Clinics in Plastic Surgery (United States) 1997,
24/1 (133-160)
Raynaud 's syndrome stands as a landmark to our
ignorance of the mechanisms involved in the
interrelationship of the central nervous system
and peripheral circulatory physiology. Proper
management for these unfortunate patients demands
an integrated comprehensive effort of the
pharmacologic, physical medical, and surgical
disciplines.
Raynaud's phenomenon in the emergency
department
Browne B.J.; Jotte R.S.; Rolnick M.
Division of Emergency Medicine, Department of
Surgery, Maryland University Medical Center, 22 S.
Greene St.,Baltimore, MD 21201-1595 United
States
Journal of Emergency Medicine (United States)
1995, 13/3 (369-378)
Raynaud 's phenomenon manifests as triphasic
color changes of the digits, induced by exposure
to low temperature or emotional stress. It is a
relatively common disorder, estimated to affect 5%
to 10% of the general population and 25% to 30% of
otherwise healthy women. Although usually self-
limiting, it can be severely painful and
debilitating, and complicated by ulcerations and
tissue necrosis. For the emergency physician
treating a patient with an acute presentation of
the phenomenon, the main challenges are to achieve
adequate pain control, reverse vasospasm, and
maintain viable tissue. Emergency treatment can
also extend to patient education and arrangement
of appropriate referrals and follow-up care.
|